TITLE

SALIVA-DERIVED PEPTIDE SHOWS PROMISE AS ORAL ANTIFUNGAL AGENT

PUB. DATE
May 2004
SOURCE
Journal of the American Dental Association (JADA);May2004, Vol. 135 Issue 5, p571
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the development of a saliva derived peptide that may be able to treat candidiasis and other fungal conditions in people undergoing chemotherapy or organ transplantation or those infected with HIV by biologists at the State University of New York in Buffalo, New York. Examination of the activity of the peptide in saliva and salt solutions containing Candidiasis albicans; Comparison of the fungal activity of the peptide with its natural L-amino acids form; Plan of the researchers to test the antifungal activity of the peptide in a mouse model of oral candidiasis.
ACCESSION #
13345902

 

Related Articles

  • In vitro Antifungal Activity of Irlbachia purpurascens, Lantana macrophylla and Kielmeyera neglecta Extracts Against Candida Isolates Collected from Patients with Vulvovaginal Candidiasis. Oliveira, G. S. A.; de Oliveira, F. F.; de Oliveira, M. C. H.; Uetanabaro, A. P. T.; Sousa, Z. L.; Andrioli, J. L. // Research Journal of Medicinal Plant;2013, Vol. 7 Issue 3, p141 

    Vulvovaginal Candidiasis (VVC) is one of the major infections that affect the female genital system, causing discomfort. The most commonly used antifungals bring severe adverse reactions and exposure to them favors the establishment of the phenomenon of resistance. Therefore, it is necessary to...

  • Posaconazole: A Viewpoint by Oliver A. Cornely. Cornely, Oliver A. // Drugs;2005, Vol. 65 Issue 11, p1568 

    This article presents an author's views on posaconazole, a new extended-spectrum triazole. The author cites the efficacy of posaconazole in the treatment of aspergillosis and candidiasis, including treatment-refractory infections. A decisive advantage of posaconazole, according to the authors,...

  • Experience Briefs. Stein, Gary E.; Smith, Curtis L. // Formulary;Oct98, Vol. 33 Issue 10, p1003 

    Focuses on the use of fluconazole in critically ill patients with candida infections. Recovery of candida isolates; Use of amphotericin B in systemic candida infections; Development of clinical algorithm for antifungal use; Description of the patients; Factors influencing the effectiveness of...

  • Candiduria: A Randomized, Double-Blind Study of Treatment with Fluconazole and Placebo. Sobel, J.D.; Kauffman, C.A.; McKinsey, D.; Zervos, M.; Vazquez, J.A.; Karchmer, A.W.; Lee, J.; Thomas, C.; Panzer, H.; Dismukes, W.E. // Clinical Infectious Diseases;1/1/2000, Vol. 30 Issue 1, p19 

    Discusses the treatment of candiduria with antimycotic agents through the analysis of a double-blind study of a sample of hospital patients. Comparison of the fungal eradication rates between patients treated with fluconozole and those treated with placebo; Inverse relation of pre-treatment...

  • Recent Drug Approvals.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1261 

    The article presents a listing of drugs that have been approved and released by the U.S. Food and Drug Administration. The brand name and generic name of the drugs include Orencia, with the generic name abatacept, used in the reduction of signs/symptoms and disease progression in moderate to...

  • Review: Oral and intravaginal agents are equally effective for treatment of uncomplicated vulvovaginal candidiasis. Harper, Diane // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p15 

    Provides information on a study that investigated whether oral and intravaginal antifungal agents are equally effective, safe and cost-effective for uncomplicated vulvovaginal candidiasis. Data sources; Study selection; Main results; Conclusions.

  • Management of Patients with Recurrent Vulvovaginal Candidiasis. Sobel, Jack D. // Drugs;2003, Vol. 63 Issue 11, p1059 

    Recurrent vulvovaginal candidiasis (RVVC) is by no means uncommon and is a source of considerable physical discomfort in addition to serving as a major therapeutic challenge. The syndrome is multifactorial in aetiology and hence management strategies must recognise the complex aetiological...

  • Micafungin: an evidence-based review of its place in therapy. de la Torre, Pola; Reboli, Annette C. // Core Evidence;2014, Vol. 9, p27 

    Invasive fungal infections have increased throughout the world. Many of these infections occur in patients with multiple comorbidities who are receiving medications with the potential for interactions with antifungal therapy that could lead to renal and hepatic dysfunction. The second marketed...

  • Oral Fluconazole for Vaginal Candidiasis. Desai, Parimal C.; Johnson, Brett A. // American Family Physician;9/15/1996, Vol. 54 Issue 4, p1337 

    Discusses the use of oral fluconazole for the treatment of vaginal candidiasis. Fungicidal action; Pharmacokinetics; Dosage; Cost; Indications and contraindications; Clinical trials that compare its efficacy with intravaginal agents; Adverse effects and drug interactions.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics